Glaucoma is the second leading cause of blindness in the world, according to the World Health Organization.

Chronic eye diseases such as Glaucoma, a group of eye diseases that may lead to permanent loss of vision – are still rampant. Many people around the world are diagnosed with this chronic disease and the effectiveness of current surgical treatment can only last for five years as observed from clinical data. Patients are struggling with compliance with the alternative, non-invasive treatment (i.e. eye drop).

New Possibilities For Seeing

Advanced Ophthalmic Innovations Pte Ltd (AOI) is a research and development innovation organisation with a heart. Our mission is to develop long term effective solutions to prevent Glaucoma patients from losing their eyesight, and make the solution accessible and affordable to patients around the world.

AOI has received CE mark for Paul® Glaucoma Implant from the European Commission (EC) and is marketed in United Kingdom, Belgium, France, Germany, Netherlands, Portugal, Spain, Australia, New Zealand, Singapore, South Africa, South Korea, Malaysia and Thailand.

We are committed to implementing, maintaining and adhering to an effective quality management system that meets international quality standards, in firm belief that in doing so, we achieve superior quality products and services to the satisfaction of customers and compliance to regulatory requirements